Viaderma Inc (OTCMKTS:VDRM) is a micro-cap name that exploded higher in February on no particular news. VDRM stock has since given those sizable gains back to the marketplace, but remains up something like 1500% off its January lows. That’s hardly a bad situation for those on board since the tail end of last year.
The company’s latest catalyst is its announcement that its President, Dr. Christopher Otiko, has received “the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for “Aqueous Topical Applications” for human and veterinarian uses. The Company plans to continue to expand its (IP) “Intellectual Property Portfolio” in 2017.”
Viaderma Inc (OTCMKTS:VDRM) bills itself as a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.
ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
The company is moving aggressively into the medicinal marijuana space.
According to company materials, “ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, Patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is known for the reduction of inflammation and for the treatment of several diseases, such as nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.”
Find out when VDRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted in the company’s most recent release, VDRM has signed a letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products.
The investment group will target sales for the new patent pending products to countries that have accepted “Medical Marijuana” and “Recreational Use” of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the “Clinical Studies” for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. “In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not,” said Dr. Otiko. “Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols.”
“We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community,” said Dr. Otiko.
The chart shows 39% tacked on to share pricing for the name in the past month. The situation may be worth watching. VDRM stock has a history of dramatic rallies. Moreover, the stock has seen interest climb, with an increase in recent trading volume of a bit less than 110% above its longer-run average levels.
The balance sheet is cash dry, but not in terrible shape by any stretch of the imagination, with virtually no cash on the books, and about $217K in total current liabilities.
Viaderma is pulling in trailing 12-month revenues of $306K. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 8.8%. We will update the story again soon as further details emerge. For continuing coverage on shares of VDRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!